Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Butnariu Monica, Quispe Cristina, Herrera-Bravo Jesús, Helon Paweł, Kukula-Koch Wirginia, López Víctor, Les Francisco, Vergara Cristian Valdés, Alarcón-Zapata Pedro, Alarcón-Zapata Barbara, Martorell Miquel, Pentea Marius, Dragunescu Aneta Anca, Samfira Ionel, Yessimsiitova Zura, Daştan Sevgi Durna, Castillo Carla Marina Salgado, Roberts Thomas H, Sharifi-Rad Javad, Koch Wojciech, Cho William C
Аннотация
Thymoquinone (TQ) is a secondary metabolite found in abundance in very few plant species including Nigella sativa L., Monarda fistulosa L., Thymus vulgaris L. and Satureja montana L. Preclinical pharmacological studies have shown that TQ has many biological activities, such as anti-inflammatory, antioxidant and anticancer. Both in vivo and in vitro experiments have shown that TQ acts as an antitumor agent by altering cell cycle progression, inhibiting cell proliferation, stimulating apoptosis, inhibiting angiogenesis, reducing metastasis and affecting autophagy. In this comprehensive study, the evidence on the pharmacological potential of TQ on pancreatic cancer is reviewed. The positive results of preclinical studies support the view that TQ can be considered as an additional therapeutic agent against pancreatic cancer. The possibilities of success for this compound in human medicine should be further explored through clinical trials.